Development of molecular-targeted therapy for non-small cell lung cancer

Chinese Journal of Clinical Oncology

Volumn 38, Issue 15, 2011, Pages 927-930

  Wang, Meng ^a   Wang, Changli ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Molecular targeted therapy; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ANGIOGENESIS; CANCER CHEMOTHERAPY; DRUG EFFECT; DRUG TARGETING; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; REVIEW;

EID: 80052825705     PISSN: 10008179     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1000-8179.2011.15.016     Document Type: Review

References (19)

1. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy[J]. Drugs, 2000, 60 Suppl 1: 15-23.
2. Engelman JA, Janne PA. Factors predicting response to EGFR tyrosine kinase inhibitors[J]. Semin Respir Crit Care Med, 2005, 26(3): 314-322. (Pubitemid 40980880)
3. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] [J]. J Clin Oncol, 2003, 21(12): 2237-2246.
4. Yang C, Yu C, Chen K, et al. A phase II study of gefitinib as first line treatment for good performance advanced or metastatic non-small-cell lung cancer in East Asian patients[J]. J Clin Oncol, 2006, 24(18s): 405.
5. Cadranel J, Quoix E, Debove P, et al. IFCT0401 trial: Phase II study of gefitinib administered as first line treatment in non-resectable, pneumonic-type adenocarcinoma(P-ADC)[J]. J Clin Oncol, 2006, 24(18s): 410.
6. Nokihara H, Ohe Y, Kawaishi M, et al. A randomized phase II study of sequential carboplatin/paelitaxel(CP)and gefitinib(G) in chemotherapy-navie patients with advanced non-small-cell lung cancer(NSCLC): Preliminary results[J]. J Clin Oncol, 2006, 24(18s): 388.
7. Mok TS, Wu YL, Thongrpasert S, et al. Gefitinib or carhoplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361 (10): 947-957.
8. Besjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study-BR. 21[J]. J Clin Oncol, 2006, 24(24): 3831-3837. (Pubitemid 46630729)
9. Akerley WL. Erlotinib as first-line treatment for untreated advance stage NSCIC with good prognosis[J]. J Clin Oncol, 2006, 24 (18s): 408.
10. Paz-Ares L, Sanchez JM, Garca-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients(P) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor(EGFR)[J]. J Clin Oncol, 2006, 24(18s): 369.
11. Jackman DM, Yeap B, Lucca J, et al. Phase II trial of erlotinib in elderly patients (age>70) with previously untreated advanced non-small cell lung cancer(NSCLC): An analysis of quality of life and symptom response[J]. J Clin Oncol, 2006, 24(18s): 406.
12. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients> or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer[J]. J Clin Oncol, 2007, 25(7): 760-766. (Pubitemid 350002874)
13. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence[J]. J Clin Oncol, 2005, 23(11): 2513-2520. (Pubitemid 47050841)
14. Leignl NB, Paz-Ares K, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2005, 23(12): 2831-2839.
15. Bissett D, O'Byrne KJ, von Pawel J, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer[J]. J Clin Oncol, 2005, 23(4): 842-849. (Pubitemid 46224184)
16. Nishio K. Resistance to target-based therapy and its circumvention [J]. Nippon Rinsho, 2004, 62(7): 1343-1347.
17. Herbst R, Johnson B, Rowbottom J, et al. ZD6474 plus docetaxel in patients with previously treated NSCLC: results of a randomized, placebo controlled phase II trial[J]. Lung cancer, 2005, 49(Suppl 2): S35.
18. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC:Final results from a two-part, double-blind, randomized phase II trial[J]. J Clin Oncol, 2006, 24 (18s): 364.